Estrogen and progesterone receptor status in breast cancer: a cross-sectional study of 450 women in Kerala, South India

World Journal of Surgical Oncology

PS Jayalakshmy¹  Terence B Culas¹  Gautham Rajan¹ 

[1] Government Medical College, Thrissur, Kerala, India

关键词: India;    postmenopausal;    premenopausal;    progesterone receptor;    estrogen receptor;    Breast cancer;   

Others  :  819743
DOI  :  10.1186/1477-7819-12-120

 received in 2014-01-16, accepted in 2014-04-04,  发布年份 2014

【 摘 要 】

Background

Hormone receptor status is an important prognostic and therapeutic tool in breast cancer. The objectives of our study were to create a database of breast cancer patients in Central Kerala between January 2010 and December 2012 and analyze the proportions of estrogen receptor and progesterone receptor positivity in premenopausal and postmenopausal women with breast cancer.

Methods

Estrogen and progesterone receptor status were evaluated by immunohistochemistry. The chi-square test was used for statistical analysis.

Results

The median age at diagnosis was 50 years while the mean age was 51.92 (SD = 11.78). 56.1% of premenopausal and 47.4% of postmenopausal patients were found to be ER positive, while PR positivity was 47.7% and 34.7% respectively in the premenopausal and postmenopausal age groups.

Conclusions

The proportions of ER and PRnegative tumors were found to be lower than reported in earlier studies on Indian populations. Contrary to expectations, the proportions of ER and PRpositivity were found to be higher in the premenopausal age group.

【 授权许可】

   
2014 Rajan et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Rastelli F, Crispino S: Factors predictive of response to hormone therapy in breast cancer. Tumori 2008, 94:370-383.
• [2]Nair MK, Sankaranarayanan R, Nair KS, Amma NS, Varghese C, Padmakumari G, Cherian T: Overall survival from breast cancer in Kerala, India, in relation to menstrual, reproductive, and clinical factors. Cancer 1993, 71:1791-1796.
• [3]Ovarian ablation in early breast cancer: overview of the randomised trials. Early breast cancer trialists’ collaborative group Lancet 1996, 348:1189-1196.
• [4]Gold EB, Bromberger J, Crawford S, Samuels S, Greendale GA, Harlow SD, Skurnick J: Factors associated with age at natural menopause in a multiethnic sample of midlife women. Am J Epidemiol 2001, 153:865-874.
• [5]McKinlay SM, Brambilla DJ, Posner JG: The normal menopause transition. Maturitas 1992, 14:103-115.
• [6]Dunnwald LK, Rossing MA, Li CI: Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res 2007, 9:R6. BioMed Central Full Text
• [7]Hammond MEH, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FCG, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, et al.: ASCO-CAP guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010, 28:2784-2795.
• [8]SEER*Stat database [http://seer.cancer.gov/statfacts/html/breast.html webcite]
• [9]Shet T, Agrawal A, Nadkarni M, Palkar M, Havaldar R, Parmar V, Badwe R, Chinoy RF: Hormone receptors over the last 8 years in a cancer referral center in India: what was and what is? Indian J Pathol Microbiol 2009, 52:171-174.
• [10]Agarwal G, Pradeep PV, Aggarwal V, Yip CH, Cheung PS: Spectrum of breast cancer in Asian women. World J Surg 2007, 31:1031-1040.
• [11]Kuraparthy S, Reddy KM, Yadagiri LA, Yutla M, Venkata PB, Kadainti SVS, Reddy RPV: Epidemiology and patterns of care for invasive breast carcinoma at a community hospital in Southern India. World J Surg Oncol 2007, 5:56. BioMed Central Full Text
• [12]Dey S, Boffetta P, Mathews A, Brennan P, Soliman A, Mathew A: Risk factors according to estrogen receptor status of breast cancer patients in Trivandrum, South India. Int J Cancer 2009, 125:1663-1670.
• [13]Manjunath S, Prabhu JS, Kaluve R, Correa M, Sridhar TS: Estrogen receptor negative breast cancer in India: do we really have higher burden of this subtype? Indian J Surg Oncol 2011, 2:122-125.
• [14]Kaul R, Sharma J, Minhas SS, Mardi K: Hormone receptor status of breast cancer in the Himalayan Region of Northern India. Indian J Surg 2011, 73:9-12.
• [15]Shahi KS, Bhandari G, Singh A: Steroid receptor status and its clinicopathological correlation in postmenopausal breast cancer patients of Kumaon region of Uttarakhand. J Cancer Res Ther 2011, 7:19-22.
• [16]Yip CH, Pathy NB, Uiterwaal CS, Taib NA, Tan GH, Mun KS, Choo WY, Rhodes A: Factors affecting estrogen receptor status in a multiracial Asian country: an analysis of 3557 cases. Breast 2011, 20(Suppl 2):S60-S64.
• [17]Chu KC, Anderson WF: Rates for breast cancer characteristics by estrogen and progesterone receptor status in the major racial/ethnic groups. Breast Cancer Res Treat 2002, 74:199-211.
• [18]Li CI, Malone KE, Daling JR: Differences in breast cancer hormone receptor status and histology by race and ethnicity among women 50 years of age and older. Cancer Epidemiol Biomarkers Prev 2002, 11:601-607.
• [19]Baum M, Sainsbury R: Recent developments in endocrine therapy of early breast cancer. Recent Adv Surg 2003, 26:183-200.